Chang Zhibo
Department of Thoracic Surgery, The Second Affiliated Hospital of Zhejiang University, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310009, P.R. China.
Exp Ther Med. 2019 Aug;18(2):1189-1195. doi: 10.3892/etm.2019.7642. Epub 2019 Jun 4.
Non-small-cell lung cancer (NSCLC) is the leading type of cancer worldwide and sex determining region Y-box 2 (SOX2) has been implicated as an oncogene in various types of cancer. In the present study, SOX2 was positively associated with NSCLC stage and lymph node metastasis. Wound healing and Transwell assays demonstrated that knockdown of SOX2 inhibited A549 and H1299 cell migration. Furthermore, it was identified that knockdown of SOX2 inhibited epithelial-to-mesenchymal transition of NSCLC cells, which was demonstrated by increased expression of epithelial-cadherin and decreased expression of vimentin, zinc finger protein SNAI1 and zinc finger protein SNAI2. It was then demonstrated that SOX2 may be targeted by microRNA (miR)-590-5p, which indicated a potential therapeutic strategy for NSCLC focusing on the miR-590-5p/SOX2 axis.
非小细胞肺癌(NSCLC)是全球主要的癌症类型,性别决定区Y盒2(SOX2)在各种癌症中被认为是一种致癌基因。在本研究中,SOX2与NSCLC分期和淋巴结转移呈正相关。伤口愈合和Transwell实验表明,敲低SOX2可抑制A549和H1299细胞迁移。此外,还发现敲低SOX2可抑制NSCLC细胞的上皮-间质转化,这通过上皮钙黏蛋白表达增加以及波形蛋白、锌指蛋白SNAI1和锌指蛋白SNAI2表达降低得以证明。随后证明SOX2可能是微小RNA(miR)-590-5p的作用靶点,这表明针对miR-590-5p/SOX2轴的NSCLC潜在治疗策略。